Lung cancer accounts for more cancer deaths than breast, prostate, colorectal and pancreatic cancer combined. With an aging population, greater intensity of cancer care, and the need for care of the growing number of cancer survivors, comparative effectiveness research opportunities will continue to emerge for this disease. In this chapter, we focus on CER opportunities in lung cancer surgery from the vantage point of those factors directly influenced by the surgeon, patient and the healthcare system.